Asco23 Lba3 Os Analysis From The Adaura Trial Of Adjuvant Osimertinib In Resected Egfr%e2%80%90mutate

Adjuvant Osimertinib In Resected Egfr Mutant Nsclc Overall Survival Analysis Of The Adaura Trial
Adjuvant Osimertinib In Resected Egfr Mutant Nsclc Overall Survival Analysis Of The Adaura Trial

Adjuvant Osimertinib In Resected Egfr Mutant Nsclc Overall Survival Analysis Of The Adaura Trial Here, we report the planned final overall survival (os) analysis from adaura. New adaura data show that adjuvant osimertinib significantly improved os, cutting the risk of death in half when compared with placebo in patients with egfr mutated nsclc (lba3).

Final Adaura Os Analysis Reinforces Adjuvant Osimertinib As A Standard Of Care For Patients With
Final Adaura Os Analysis Reinforces Adjuvant Osimertinib As A Standard Of Care For Patients With

Final Adaura Os Analysis Reinforces Adjuvant Osimertinib As A Standard Of Care For Patients With Adjuvant osimertinib had a safety profile consistent with that in the primary analysis. conclusions: adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, egfr mutated, stage ib to iiia nsclc. Lba3: overall survival analysis from the adaura trial of adjuvant osimertinib in patients with resected egfr‐mutated (egfrm) stage ib–iiia non small cell lun. Final overall survival analysis of the phase iii adaura trial of adjuvant osimertinib after complete resection in stage ib iiia egfr mutated nsclc, presented at asco 2023 and reported by clinical care options (cco). Presentation of abstract lba3, overall survival analysis from the adaura trial of adjuvant osimertinib in patients with resected egfr‑mutated (egfrm) stage ib–iiia non small cell lung cancer (nsclc).

Final Adaura Os Analysis Reinforces Adjuvant Osimertinib As A Standard Of Care For Patients With
Final Adaura Os Analysis Reinforces Adjuvant Osimertinib As A Standard Of Care For Patients With

Final Adaura Os Analysis Reinforces Adjuvant Osimertinib As A Standard Of Care For Patients With Final overall survival analysis of the phase iii adaura trial of adjuvant osimertinib after complete resection in stage ib iiia egfr mutated nsclc, presented at asco 2023 and reported by clinical care options (cco). Presentation of abstract lba3, overall survival analysis from the adaura trial of adjuvant osimertinib in patients with resected egfr‑mutated (egfrm) stage ib–iiia non small cell lung cancer (nsclc). “the practice changing disease free survival data from our primary analysis together with the overall survival benefits reported instill confidence that adjuvant osimertinib is the standard of care for patients with resected egfr mutated stage ib to iiia nsclc. These updated data demonstrate prolonged dfs benefit over placebo, reduced risk of local and distant recurrence, improved cns dfs, and a consistent safety profile, supporting the efficacy of adjuvant osimertinib in resected egfr mutated nsclc. Adaura is the first global phase iii study to demonstrate a statistically significant dfs and os benefit with targeted treatment for patients with egfr m stage ib to iiia nsclc (abstract lba3). Conclusions: adjuvant osimertinib demonstrated an unprecedented, highly statistically significant and clinically meaningful os benefit in patients with egfrm stage ib–iiia nsclc after complete tumor resection, with or without adjuvant chemotherapy.

Comments are closed.